ClinicalTrials.gg
RecruitingNCT06379139BIOPAVIR2Updated Apr 23, 2024

Dynamic Full-field Optical Coherence Tomography for Structural and Microbiological Characterization of Endotracheal Tube Biofilm in Critically Ill Patients

An observational study in Healthcare Associated Infection, Critically Ill and Endotracheal Tube, sponsored by Centre Hospitalier Universitaire Dijon. Recruiting at 2 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-04-23.

Sponsored by Centre Hospitalier Universitaire Dijon · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Mar 2025, 1 year 8 months ago, but the record still lists the study as recruiting.
  • Started Mar 2024; still recruiting 2 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
80
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 47 studies in Cross Infection with a site in France — 8 open to participants now, 9 under way, 1 of them phase 3. Cross Infection · France.

Planned enrollment
18th of 24
80 · median 496
Started
2024
with 2 others
Observational
24 of 47
4 open now
Registered
40th of 47
by date

Among the 47 studies in Cross Infection with a site in France, this one is the 18th largest by planned enrollment of the 24 observational ones that give a count, is one of 3 that started in 2024, is one of 24 observational ones, and was the 40th registered.

Cross Infection

287 studies on the registry are indexed under Cross Infection; 47 are open to participants now.

Browse Cross Infection studies →

Open to participants now

8 of the 47 studies in Cross Infection with a site in France are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 27 Cross Infection studies recruiting now, 23 (85%) set no upper age limit and 2 (7%) stop at 75 or younger; 5 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 47 studies in Cross Infection with a site in France, or all of them as a file.
02

Study summary

Biofilm is a microstructure organised into aggregates of microbiological species within a polymeric matrix. As early as the 2000s, the Centers for Disease Control and Prevention (CDC) recognised the possible role of the biofilm lining endotracheal endotracheal tubes in the development of ventilator-associated pneumonia (VAP) , the most common infection in intensive care, with a high morbidity and mortality rate and a significant increase in hospital costs.

Targeting biofilm therefore now appears to be a new area of interest for limiting the risk of VAP, and this rationale has led to the development of an intraluminal for abrading biofilm deposited on the inside of the intubation probe

. Evaluation of this type of strategy nevertheless justifies the introduction of more precise methods for characterisation of the biofilm.

To this end, the investigator carried out an initial clinical study describing the biofilm on intubation probes, BIOPAVIR 1, showing the existence of several biofilm structures, each associated with a specific microbiological signature. Several limitations including a lack of power due to an insufficient number of patients and the use of number of patients, and the use of a confocal microscopy technique with poor axial without the possibility of acquiring metabolic images of the biofilm.

Based on the previous description of biofilm by optical coherence tomography (OCT), and a recent experience with an optimised form of high-resolution OCT, called full-field OCT, the investigator hypothesise that full-field OCT will allow more accurate characterisation of biofilm, due to its high spatial resolution and its potential ability to capture metabolic activity in the biofilm BIOPAVIR 2 proposes to use the performance of full-field OCT to better characterise the biofilm lining endotracheal tubes in patients undergoing mechanical ventilation in intensive care units. This project represents a first step towards understanding the link between the development of biofilm on intubation and the occurrence of VAP

03

Conditions studied

  • Healthcare Associated Infection
  • Critically Ill
  • Endotracheal Tube
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patient over 18 years of age having declared their nonobjection and exposed to mechanical ventilation for at least two calendar days

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient or relative informed of the study and having declared their nonobjection
  • Patient over 18 years of age
  • Patient exposed to mechanical ventilation for at least two calendar days

Exclusion criteria

Exclusion Criteria:

  • Patient unable to declare their nonobjection
  • Patient whose endotracheal tube collection is impossible
  • Patient whose endotracheal tube is collected following self-extubation (sample contamination)
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
80 participants (estimated)
Patient registry
No

Groups and cohorts

  • BIOPAVIR 2 cohort

    Adult critically ill patients (\> 18 years of age) exposed to endotracheal tube for at least two calendar days

    Other: •Dynamic Full-Field Optical Coherence Tomography analysis of endotracheal tube

Interventions

  • Other•Dynamic Full-Field Optical Coherence Tomography analysis of endotracheal tube

    Dynamic full-field optical coherence tomography analysis of endotracheal tube sections to better apprehend strucural characterization of endotracheal tube-deposited biofilm

06

What researchers measure

Primary outcomes

  1. Dynamic Full-Field Optical Coherence Tomography-based biofilm structure type

    shape data

    Time frame: At Day 0, within 72hours following endothracheal tube removal

  2. type of microbiological associated with each shape

    Time frame: At Day 0, within 72hours following endothracheal tube removal

07

Study locations

2 of 2 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2024 (actual). Primary completion is estimated for Mar 2025, 12 months after the start.

Of 57 non-industry observational studies under Cross Infection, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 65. This study's planned 12 months is below that.

Counting every sponsor, half of 57 studies reached it within 28 months; a quarter within 14 and three quarters within 65.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 4, 2024
First posted
Apr 23, 2024
StartActual
Mar 1, 2024
Primary completionEst.
Mar 2025
CompletionEst.
Mar 2025
Last update
Apr 23, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 23, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06379139
Responsible party
Sponsor
First posted
Apr 23, 2024
Start date
Mar 1, 2024
Primary completion
Mar 2025 (estimated)
Completion
Mar 2025 (estimated)
Last update
Apr 23, 2024

Study contacts

Thomas MALDINEY
Contact
thomas.maldiney@ch-chalon71.fr
385910474 ext. +33
Thomas MALDINEY
principal investigator · CH William Morey

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion